Title Segment Summary Type Price Published
Marché des Formules Nutritionnelles utilisées pour la culture des microalgues Bioproduction

La culture des microalgues nécessite six critères indispensables pour leur croissance et également pour permettre la photosynthèse : 

- Température, 
- Salinité, 
- Composition du milieu de culture : nutriments, 
- pH,  
- Luminosité,  
- CO2 utilisé comme source de carbone pour la photosynthèse. 

Parmi les nutriments essentiels, il y a les macronutriments avec principalement l'azote et le phosphore. La culture des microalgues nécessite aussi un apport en oligoéléments et en vitamines.  
Des milieux de culture « type » ont été mis au point pour la culture des microalgues en laboratoire et en photobioréacteurs. La composition de ces milieux diffère selon les besoins nutritionnels des espèces de microalgues.

Production 5000 euros 2012-01-17
Marché de la culture des microalgues et leurs applications Bioproduction

La principale application de la biomasse des microalgues commerciales est la nutrition humaine. En 2010, les aliments fonctionnels et les compléments alimentaires représentent plus de 85 % de la production totale. L'application en alimentation animale, y compris l'aquaculture, les animaux de compagnie et les bovins, représente 14 % de la production totale. Les produits cosmétiques et d'autres applications nécessitent moins de 500 tonnes de biomasse sèche, principalement utilisés pour la production d'extraits.

Le marché global des microalgues au niveau producteur était d'environ 800 millions de dollars en 2010, avec un taux de croissance annuelle attendue entre 7 % et 10 % pour les cinq prochaines années selon l'application finale. La commercialisation de biofuel encore incertaine en termes de faisabilité économico-technique et de projection dans le temps a été volontairement séparée de l'analyse du marché concret actuel (chiffre d'affaires) dans les projections de l'étude.

Market Report 7500 euros 2012-01-17
Microalgae Market and Application Outlook Bioproduction

The term “microalgae” defines all microscopic algae, unicellular or filamentous, with any relation with the taxonomy. Microalgae are an extremely heterogeneous group of microorganisms. This group counts more than 50,000 species (estimation) very different phylogenetically. This diversity makes microalgae a potentially rich source of avast array of chemical products with applications in the feed, food, cosmetic, pharmaceutical and even fuel industries.

Microalgae can be produced using a wide variety of methods, ranging from closed fully controlled methods to less predictable methods in outdoor tanks. The terminologies used to describe the type of algal culture include indoor/oudoor, open/closed, axenic, batch, continuous and semi-continuous.

Open pond systems are shallow ponds in which algae are cultivated. Nutrients can be provided through runoff water from nearby land areas or by channeling the water from sewage/water treatment plants. Photobioreactors are different types of tanks or closed systems in which algae are cultivated. Algal cultures consist of a single or several specific strains optimized for producing the desired product. About ten microalgae are used for commercial applications. They are used as a whole without transformation (named whole algae in this report) or are used to produce extracts of interest (named extract in this report).

The global production of microalgae for all applications is estimated. The Algae mostly produced are described.The two algae with the biggest production are Spirulina and Crypthecodinium. Two types of products with microalgae are available. Whole microalgae biomass and extracts from microalgae. Three main extracts come from microalgae: carotenoids, phycobiliproteins and antioxidants. Main microalgae market applications are: human and animal nutrition, cosmetics and research.  

See also

Market Report 7500 euros 2011-04-19
European Contract Biomanufacturing Organizations - CbMO Market Outlook Biomanufacturing

From the exponential growth of the "modern" biotechnology industry in the 1990's the creation of Contract Manufacturing Organizations (CMOs) has followed to supply the increasing needs of production capacity and cost savings. Yet at that time, only a few CMOs existed. Back then in the pharmaceutical industry, only 5% of new drug approvals by the FDA (Food and Drug Administration) were issued from biotechnology companies and in the industrial biotechnology sector most enzymes were still produced by extraction or by chemical synthesis.

166 contract biomanufacturing Organizations were identified in the European biomanufacturing market accounting for 229 production sites located in Europe.

Two kinds of CMOs exist in Europe: 73% "Multipurpose" CMOs and 27% AB-only CMOs for custom monoclonal and polyclonal antibody manufacturing.

49% of Biomanufacturing CMOs are located in Western Europe. More than half of all AB-only biomanufacturers (52%) are located in UK and France. Four main expression systems are used by contract biomanufacturing organizations: microbial, mammalian, transgenic animals and plant cells. Microbial platform still comes out on top of expression system used in Contract biomanufacturing with more than 83% of utilization by Multi-P CMOs, followed by mammalian cell culture (35%).

European contract biomanufacturing organizations supply 72% pharmaceutical, 45% food and 25% feed markets. 37 European CMOs (for 69 production sites) are able to supply commercial bioproducts volumes. These facilities represent 40% of the 172 multi-purpose biomanufacturing sites established in Europe. See also

Market Report 4990 euros 2011-03-09
Alzheimer Disease Pharmaceutical

Alzheimer's disease (AD) is by far the most common cause of dementia associated with aging; it accounts for more than 60% of all dementia. Alzheimer's disease is characterized by an insidious onset and slow deterioration in cognition, functional ability (e.g., activities of daily living), behavior, and mood. In USA, AD is the 7th leading cause of mortality. 
In 2010, more of 21 million people will be affected by this disease in the world. As the world population ages, this number will increase.
See also

Market Report 3500 euros 2010-06-01
AZD‐9668 Pharmaceutical

The term chronic obstructive pulmonary disease (COPD) covers a complex group of disorders characterized by a progressive development of airflow limitation. Key risk factors of the disease are cigarette smoke and air pollution. In addition, a genetic component is involved in the development  of COPD. It is set to become the third leading cause of death in the developed world by 2020.
AZD‐9668 is a protease (lactase) inhibitor.

Product Report 1500 euros 2010-04-01
Cepheid Swot Analysis Diagnostics

Cepheid (NASDAQ: CPHD) is a leading nucleic acid (NA) testing company based in Sunnyvale, CA. Founded in 1996, the company develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets.

Company Profile 350 euros 2010-02-03
P38 Kinase Inhibitors Pharmaceutical

P38 Kinase is a convergence point for multiple signaling pathways involved in inflammation. Because of P38 Kinase's central role, inhibitors of the enzyme have long been sought as potential drugs for a variety of inflammatory diseases.

Mitogen-activated protein kinases (MAPK) are intracellular signaling molecules involved in cytokine synthesis. Several classes of mammalian MAPK have been identified, including extracellular signal-regulated kinase, c-jun N-terminal kinase, and p38 MAP kinase. p38 is a key MAPK involved in tumor necrosis factor and other cytokine production, as well as enzyme induction (cyclooxygenase-2, inducible nitric oxide synthase, and matrix metalloproteinases) and adhesion molecule expression. The role of MAPK in inflammation makes them attractive targets for new therapies.

Product Report 850 euros 2010-02-01
Qiagen: Company Profile and SWOT Analysis Diagnostics

Qiagen develops and markets biological sample preparation and analysis products for academic, biopharmaceutical and molecular diagnostics companies. These products are considered standards by these customers.
Qiagen has experienced impressive double-digit revenue growth over the last few years, in part driven by increased exposure to MDx.
Over the last few years, Qiagen has started a transition from life science research tools to molecular diagnostic(MDx),triggered by the strategic acquisition of Digene. This transaction reflects the increasing interest research tools companies have for the attractive MDx market, a ~$4B market that is experiencing double digit growth.

Company Profile 700 euros 2009-12-03
Dry Eye Disease Pharmaceutical

Dry eye disease (DED) is one of the most frequently encountered ocular morbidities. 25 % percent of patients who visit ophthalmic clinics report symptoms of dry eye, making it a growing public health problem and one of the most common conditions seen by eye care practitioners. Historically, the term "Keratoconjunctivitis sicca" can be attributed to the Swedish ophthalmologist Henrik SC jögren. He was the first to refer to the triad of Keratoconjunctivitis sicca, dry mouth, and joint pain, which occurs mainly in women (90% of the cases) (, and in 1950 Andrew De Roetth introduced the term "dry eye". For many decades, DED was thought to be limited to dryness of the eyes due to reduction of the aqueous phase of the tear film. In 1995, DED was defined as a complex multifaceted group of medical and ocular diseases that is due to decreased tear production and/or increased tear evaporation. In 2007, the International Dry Eye Workshop (DEWS) revised the original definition and classification scheme of DED and developed a new definition, as well as a three‐part classification of DED based on etiology, mechanism, and severity of the disease.
See also:

Disease Report 4500 euros 2009-12-01
Molecular Diagnostics: Market Segmentation and Opportunities Diagnostics

Molecular diagnostics (MDx) is the fastest growing segment of the in vitro diagnostics industry (IVD). With a market size of ~$4B in 2009, and a double digit growth rate, this attractive segment continues to be a major contributor in the evolution of the healthcare landscape.

MDx involves platforms and assays that leverage multiple technologies to identify genetic variations in individual patients. These technologies offer significant advantages such as time-to-result and cost-effectiveness over culture-based or immune-based techniques.

This report reviews the market size, growth, segments and trends of the MDx industry from 2006 to 2012. The market is segmented to provide insights on specific growth opportunities by therapeutic areas, analytes tested (i.e., plex level), test rationale, test location and geography.

Major competitors are reviewed along with their key platforms. Competitors shaping the industry include BioPharma (e.g., Abbott, Roche), IVD/MDx pure-play companies (e.g., BioMerieux, Cepheid, Gen-probe) or research tool companies (e.g., Illumina, Life Technologies).

Market Report 1500 euros 2009-11-30
Roflumilast (Daxas) Pharmaceutical

Chronic obstructive pulmonary disease (COPD) remains a significant area of unmet medical need. It is a progressive and irreversible lung disease that restricts breathing. 

Daxas (Roflumilast) is a phosphodiesterase-4 (PDE4) inhibitor that is being developed to treat the underlying inflammation in COPD and related inflammatory diseases. It could be both the first PDE4 inhibitor and the first orally administered anti-inflammatory treatment for COPD patients. As a once-daily, non-steroidal anti-inflammatory treatment, Daxas offers the opportunity for a new approach to the treatment of COPD.

Product Report 1500 euros 2009-11-25
Systemic Lupus Erythematosus (SLE) Pharmaceutical

Lupus is one of many disorders of the immune system known as autoimmune diseases. In autoimmune diseases, the immune system turns against parts of the body it is designed to protect.
This leads to inflammation and damage to various body tissues. Lupus can affect many parts of the body, including the joints, skin, kidneys, heart, lungs, blood vessels, and brain. Although people with the disease may have many different symptoms, some of the most common ones include extreme fatigue, painful or swollen joints (arthritis), unexplained fever, skin rashes, and kidney problems.

Market Report 3500 euros 2009-11-25
Wegener's Granulomatosis (WG) Pharmaceutical

Wegener's granulomatosis is a necrotizing granulomatous vasculitis with the prevalence of 3 in 100 000. The disease was first described in 1931 by a medical student in Germany named Heinz Klinger. Afterwards, in 1936 Dr. Wegener a young German pathologist gave a detailed explanation regarding three patients suffering from this disease.Although it is an uncommon disease, if not diagnosed and treated in-time my cause renal failure and severe pulmonary complications including diffuse pulmonary hemorrhage. Therefore, timely diagnosis and treatment is important in preventing related morbidity and mortality. Pulmonary involvement is the most common form of the disease manifested in 95% of cases but onset of the disease with rare symptoms such as proptosis (in 2% of the cases) and hyperthyroidism (in 1% of the cases) has been reported as well.

Disease Report 1500 euros 2009-11-25
Fluidigm Due Diligence: Company Profile, SWOT Analysis and Market Opportunity Life Science

Fluidigm is a life science company that develops and distributes instruments and chips for genomic analysis and X-ray crystallography applications. The company owns a disruptive and scalable integrated fluidic circuits (IFC) technology.

This technology enables the execution of thousands of experiments in parallel in nanoliter volumes, and facilitates implementation of experiments with a complex design.

Since its inception in 1999, Fluidigm has incurred >$150M in operating losses. While profitability in the next 1-2 years is unlikely, Fluidigm has strong revenue potential given its deep intellectual property portfolio and growth of its targetmarkets.

Company Profile 800 euros 2009-09-29
Durable Medical Equipment: U.S. Market Size, Growth and Trends Healthcare

Durable medical equipment (DME) is defined as instruments and products used for medical purposes and that can withstand repeated usage. DME is used primarily to help improve the quality of life of patients with injuries or illnesses.

Different stakeholders segment DME in different ways, making the market more or less inclusive. For the purpose of this report, we divided the DME market in six therapeutic segments: Home respiratory therapy, Home infusions, Diabetes supplies, Patient positioning, Patient mobility, Other equipment.

Using this segmentation, we estimate that the U.S. DME market reached ~$27B in 2009. We expect this market to grow 6% per annum to $34B by 2013, with various segments growing in the mid- to high- single-digits. We review the factors that will be driving and moderating this growth, such as patient satisfaction,outcome and cost. 
DME products are distributed primarily by national and local providers; other channels, such as 3rd party distributors or mail-in orders exist for some channels.

Market Report 1300 euros 2009-09-28
Drug Delivery Market Pharmaceutical

The global drug delivery market has grown from an estimated $26bn in 2000 to approximately $60bn in 2006.
The market has witnessed rapid expansion due to patent expiration of blockbuster drugs, stringent FDA regulations, an increased focus on the expansion of products' life-cycle, cost-effective production of neoteric delivery vehicles, and the emergence of a range of delivery solutions and hybrid platforms.

Market Report 3000 euros 2009-01-01